TrialDrug design, development and therapy2017

A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers.

Jieon Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.